Karyopharm is hoping to broaden the label for its first-in-class blood cancer therapy Xpovio to include myelofibrosis, even ...

The group, known as LAPSUS$, maintain that they have stolen around 3GB of compressed AZ data, but somewhat unusually are ...

MSD's Keytruda is poised to end a 20-year drought in new advances in NHS treatment for early-stage head and neck cancer, ...

BIO-Europe Spring arrived in Lisbon, Portugal yesterday, running from 23 rd to 25 th March. Combined with the LSX World ...

Gilead Sciences has built up its position in the hot area of T-cell engagers (TCEs) for autoimmune diseases with an agreement ...

As health systems seek to balance innovation with the need to address sustainability, increasing attention is being paid to ...

At BIO-Europe Spring 2026 in Lisbon, Portugal web editor Nicole Raleigh sat down with Robert Jacks, CEO of Sparrow ...

MSD is paying $20 million upfront to activate an alliance with Flagship Pioneering's Quotient Therapeutics that will focus on finding new therapeutic targets in inflammatory bowel disease (IBD). The ...

Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 ...

The FDA has scheduled a public meeting to discuss its Commissioner's National Priority Voucher (CNPV) programme, amid ...

Novo Nordisk is facing generics of its GLP-1 drug in India, Atrogi is testing a new weight loss approach, and there's new ...

California biotech Kali Therapeutics has snagged its first major pharma partner, Sanofi, which is committing $180 million in near-term payments for rights to a T-cell engager (TCE) for autoimmune ...